Vertex Pharmaceuticals Inc
NASDAQ:VRTX

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Watchlist
Price: 452.39 USD 0.45%
Market Cap: 116.5B USD
Have any thoughts about
Vertex Pharmaceuticals Inc?
Write Note

Relative Value

The Relative Value of one VRTX stock under the Base Case scenario is 261.97 USD. Compared to the current market price of 452.39 USD, Vertex Pharmaceuticals Inc is Overvalued by 42%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

VRTX Relative Value
Base Case
261.97 USD
Overvaluation 42%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
33
vs Industry
41
Median 3Y
9.3
Median 5Y
9.5
Industry
7.7
Forward
10.6
vs History
vs Industry
6
Median 3Y
25
Median 5Y
25.6
Industry
22.2
Forward
1 118.2
vs History
vs Industry
6
Median 3Y
21.1
Median 5Y
22.1
Industry
22.3
vs History
vs Industry
5
Median 3Y
23.1
Median 5Y
24.1
Industry
25.5
vs History
28
vs Industry
12
Median 3Y
5.9
Median 5Y
6.3
Industry
2.5
vs History
30
vs Industry
36
Median 3Y
8.2
Median 5Y
8.4
Industry
7.8
Forward
9.9
vs History
30
vs Industry
31
Median 3Y
9.3
Median 5Y
9.6
Industry
9
vs History
28
vs Industry
4
Median 3Y
19.4
Median 5Y
19.4
Industry
3.9
Forward
82.2
vs History
26
vs Industry
4
Median 3Y
20.1
Median 5Y
20.4
Industry
3.6
Forward
180.2
vs History
vs Industry
5
Median 3Y
18.5
Median 5Y
19.4
Industry
5.2
vs History
vs Industry
5
Median 3Y
19.9
Median 5Y
20.6
Industry
3.3
vs History
42
vs Industry
23
Median 3Y
9.1
Median 5Y
9.9
Industry
4.6

Multiples Across Competitors

VRTX Competitors Multiples
Vertex Pharmaceuticals Inc Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
117B USD 11 -243 24.2 25.5
FR
Pharnext SCA
OTC:PNEXF
6T USD 37 888 840.5 -180 080 -218 674.5 -216 179.2
US
Abbvie Inc
NYSE:ABBV
314.4B USD 5.7 61.9 15.4 23.7
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 4.9 37.4 17.5 33.1
US
Gilead Sciences Inc
NASDAQ:GILD
112.5B USD 4 892.3 9.9 9.9
US
Epizyme Inc
F:EPE
94.1B EUR 1 859.4 -474.5 -516.7 -502.9
AU
CSL Ltd
ASX:CSL
133.6B AUD 5.9 32.9 20.3 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.3B USD 6 17.7 16.1 17.9
US
Seagen Inc
F:SGT
39.3B EUR 17.9 -54.9 -59 -53.2
NL
argenx SE
XBRU:ARGX
34.5B EUR 18.6 -130.6 -105.1 -76.6
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
31.8B USD 15.2 -95.6 -227.4 -159.8
P/E Multiple
Earnings Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average P/E: 208.4
Negative Multiple: -243
42%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -180 080 N/A
US
Abbvie Inc
NYSE:ABBV
61.9
412%
US
Amgen Inc
NASDAQ:AMGN
37.4
73%
US
Gilead Sciences Inc
NASDAQ:GILD
892.3
75%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -474.5 N/A
AU
CSL Ltd
ASX:CSL
32.9
65%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.7
43%
US
S
Seagen Inc
F:SGT
Negative Multiple: -54.9 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -130.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -95.6 N/A
EV/EBITDA Multiple
EBITDA Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average EV/EBITDA: 17.2
24.2
38%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -218 674.5 N/A
US
Abbvie Inc
NYSE:ABBV
15.4
28%
US
Amgen Inc
NASDAQ:AMGN
17.5
63%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
12%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -516.7 N/A
AU
CSL Ltd
ASX:CSL
20.3
42%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
16.1
46%
US
S
Seagen Inc
F:SGT
Negative Multiple: -59 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -105.1 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -227.4 N/A
EV/EBIT Multiple
EBIT Growth
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Average EV/EBIT: 22.6
25.5
44%
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -216 179.2 N/A
US
Abbvie Inc
NYSE:ABBV
23.7
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -502.9 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
17.9
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53.2 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.6 N/A
US
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
Negative Multiple: -159.8 N/A

See Also

Discover More
Back to Top